Back to today’s briefing

Story perspectives

FDA Suspends Valneva's Chikungunya Vaccine After Deaths

8/25/2025

24 2

Summary

Story summary

The FDA suspended Valneva's chikungunya vaccine, Ixchiq, following serious adverse reactions, including one death from encephalitis.
This suspension halts all marketing and distribution of the vaccine in the U.S.
Valneva will evaluate the financial impact but maintains current revenue forecasts.
Ixchiq generated $10.2 million in sales, part of Valneva's total sales of $123 million in early 2025.

1 of 1

Story summary

The FDA suspended Valneva's chikungunya vaccine, Ixchiq, following serious adverse reactions, including one death from encephalitis.
This suspension halts all marketing and distribution of the vaccine in the U.S.
Valneva will evaluate the financial impact but maintains current revenue forecasts.
Ixchiq generated $10.2 million in sales, part of Valneva's total sales of $123 million in early 2025.